The GLP-1 receptor agonist liraglutide inhibits necroptosis and neuroinflammation in a mouse model of Parkinson’s disease with diabetes co-morbidity
ObjectiveTo investigate the effects of the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide on motor function, necroptosis, and neuroinflammation in the brain in mice with diabetic Parkinson’s disease (PD) and its possible mechanism.MethodsWe prepared a diabetic model with streptozotocin, followed by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced diabetic PD model, along with liraglutide or saline intervention, and the control group with […]
Tirzepatide and Brain Disease; Lamotrigine Warning Challenged; APOE4’s Links
(MedPage Today) — Tirzepatide (Mounjaro, Zepbound) may have neuroprotective mechanisms against Alzheimer’s disease and dementia, a review suggested. (Metabolic Brain Disease)
An instantaneous brain-to-voice neuroprosthesis helped a man with amyotrophic…
Psychiatric disorders less likely after weight-loss surgery than treatment with GLP-1s
People who have metabolic and bariatric surgery are significantly less likely to develop psychiatric disorders compared to those who take weekly injections of GLP-1 anti-obesity medications, according to a new study presented today at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting. Over a five-year period, the risk of developing […]
Bariatric surgery leads to greater weight loss than GLP-1 drugs after two years
Sleeve gastrectomy and gastric bypass were associated with about five-times more weight loss than weekly injections of GLP-1 receptor agonists semaglutide or tirzepatide, at the end of two years, according to a new head-to-head real-world study presented today at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting.
Bariatric surgery linked to lower risk of psychiatric disorders than GLP-1 drugs
People who have metabolic and bariatric surgery are significantly less likely to develop psychiatric disorders compared to those who take weekly injections of GLP-1 anti-obesity medications, according to a new study presented today at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting.
STAT+: Lilly adds highest Zepbound doses to DTC offering
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, let’s get straight to the news today. The need-to-know this morning Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus a CVR potentially worth another $300 million. […]
Ozempic outperforms another diabetes drug for reducing stroke risk
Type 2 diabetes patients taking semaglutide, often sold as Ozempic or Wegovy, have a slightly lower risk of stroke compared to patients taking another diabetes drug—empagliflozin. International researchers studied data from 7,899 patients treated with semaglutide and 7,899 treated with empagliflozin to look for differences in the risk of death, heart attack, stroke, heart failure and an irregular heartbeat.